Detail akcie Vertex Pharma online

Business Summary: Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Vertex Pharmaceuticals Incorporated revenues increased 20% to $6.63B. Net income increased 59% to $2.5B. Revenues reflect TRIKAFTA segment increase of 41% to $5.67B, Europe segment increase of 46% to $2.02B, United States segment increase of 9% to $4.24B. Net income benefited from Research and development Expenses - Bala decrease of 47% to $1.14B (expense).